Anti-EMP2 ADCC Enhanced Antibody (PG-101) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a novel IgG1 monoclonal antibody to EMP2, PG-101 treatment in the primary tumor is sufficient to reduce secondary tumor formation in triple negative breast cancer cells on the order of 1:20, 000 compared to the control treated mice. PG-101 in combination with docetaxel can cure up to 80% of animals treated. This effect is lasting as these mice have shown no rebound in tumor load more than 2 months following the last treatment. Collectively, these results show that PG-101 therapy has the potential to revolutionize the outcomes for women with breast cancer.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-317 | Recombinant Anti-human EMP2 Antibody | WB, Neut, FuncS | IgG |
There are currently no Customer reviews or questions for AFC-219CL. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.